Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

Phase 2positiveCAR-TPositive

AI Analysis

Summary

Anixa Biosciences announced treatment of a second patient in the fifth cohort of its ovarian cancer CAR-T clinical trial, with positive safety and efficacy data including multiple patients surviving beyond one year without dose-limiting toxicities.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Second patient in Cohort 5 treated; multiple patients surviving more than one year with one beyond two years; no dose-limiting toxicities observed

Importance:6/10

Sentiment:

0.70

CAR-TOvarian CancerClinical TrialImmunotherapyDose Escalation

Related Companies

$ANIX

Read the original article

Published by PR Newswire Biotech on October 1, 2026 12:35 PM

Read Original